Skip to main content
. 2022 Mar 25;14(4):683. doi: 10.3390/v14040683

Table 1.

High stringency Tier 2 criteria resolves circRNAs exclusive to viremic patients.

Members of Cohort Prevalence of Unique circRNAs
Proportion Abundance Pre-ART a Post-ART
100% 19 7 0
75% 14 65 61
50% 9 147 167
25% 5 339 357
15% 3 588 638
5% 1 2720 2675

a ART, antiretroviral therapy.